Literature DB >> 27908834

Gamma secretase inhibitor impairs epithelial-to-mesenchymal transition induced by TGF-β in ovarian tumor cell lines.

M C Pazos1, D Abramovich2, A Bechis3, P Accialini4, F Parborell5, M Tesone6, G Irusta7.   

Abstract

Ovarian cancer is characterized by being highly metastatic, a feature that represents the main cause of failure of the treatment. This study investigated the effects of γ-secretase inhibition on the TGF-β-induced epithelial-mesenchymal transition (EMT) process in ovarian cancer cell lines. SKOV3 cells incubated in the presence of TGF-β showed morphological and biochemical changes related to EMT, which were blocked by co-stimulation with TGF-β and the γ-secretase inhibitor DAPT. In SKOV3 and IGROV1 cells, the co-stimulation blocked the cadherin switch and the increase in the transcription factors Snail, Slug, Twist and Zeb1 induced by TGF-β. DAPT impaired the translocation of phospho-β-catenin to the inner cell compartment observed in TGF-β-treated cells, but was not able to block the induction at protein level induced by TGF-β. Moreover, the inhibitor blocked the increased cell migration and invasiveness ability of both cell lines induced by TGF-β. Notch target genes (Hes1 and Hey1) were induced by TGF-β, decreased by DAPT treatment and remained low in the presence of both stimuli. However, DAPT alone caused no effects on most of the parameters analyzed. These results demonstrate that the γ-secretase inhibitor used in this study exerted a blockade on TGF-β-induced EMT in ovarian cancer cells.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cadherin switch; Epithelial-to-mesenchymal transition; Gamma secretase inhibitor; Metastasis; Ovarian cancer; TGF-β

Mesh:

Substances:

Year:  2016        PMID: 27908834     DOI: 10.1016/j.mce.2016.11.025

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  8 in total

Review 1.  Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance.

Authors:  Tyler R McCaw; Evelyn Inga; Herbert Chen; Renata Jaskula-Sztul; Vikas Dudeja; James A Bibb; Bin Ren; J Bart Rose
Journal:  Oncologist       Date:  2021-01-02

2.  Notch signaling inhibitor DAPT provides protection against acute craniocerebral injury.

Authors:  Hong-Mei Zhang; Pei Liu; Cheng Jiang; Xiao-Qing Jin; Rui-Ning Liu; Shun-Qing Li; Yan Zhao
Journal:  PLoS One       Date:  2018-02-15       Impact factor: 3.240

Review 3.  Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu.

Authors:  Michela Colombo; Leonardo Mirandola; Maurizio Chiriva-Internati; Andrea Basile; Massimo Locati; Elena Lesma; Raffaella Chiaramonte; Natalia Platonova
Journal:  Front Immunol       Date:  2018-08-14       Impact factor: 7.561

Review 4.  Notch signaling in female cancers: a multifaceted node to overcome drug resistance.

Authors:  Maria V Giuli; Angelica Mancusi; Eugenia Giuliani; Isabella Screpanti; Saula Checquolo
Journal:  Cancer Drug Resist       Date:  2021-08-05

5.  Numb-PRRL promotes TGF-β1- and EGF-induced epithelial-to-mesenchymal transition in pancreatic cancer.

Authors:  Weiwei Sheng; Jingtong Tang; Rongxian Cao; Xiaoyang Shi; Yuteng Ma; Ming Dong
Journal:  Cell Death Dis       Date:  2022-02-23       Impact factor: 8.469

6.  Concomitant attenuation of HMGCR expression and activity enhances the growth inhibitory effect of atorvastatin on TGF-β-treated epithelial cancer cells.

Authors:  Katsuhiko Warita; Takuro Ishikawa; Akihiro Sugiura; Jiro Tashiro; Hiroaki Shimakura; Yoshinao Z Hosaka; Ken-Ichi Ohta; Tomoko Warita; Zoltán N Oltvai
Journal:  Sci Rep       Date:  2021-06-17       Impact factor: 4.379

7.  miR-205-5p inhibits cell migration and invasion in prostatic carcinoma by targeting ZEB1.

Authors:  Lianpeng Li; Shouqiang Li
Journal:  Oncol Lett       Date:  2018-05-31       Impact factor: 2.967

8.  Gremlin Regulates Tubular Epithelial to Mesenchymal Transition via VEGFR2: Potential Role in Renal Fibrosis.

Authors:  Laura Marquez-Exposito; Carolina Lavoz; Raul R Rodrigues-Diez; Sandra Rayego-Mateos; Macarena Orejudo; Elena Cantero-Navarro; Alberto Ortiz; Jesús Egido; Rafael Selgas; Sergio Mezzano; Marta Ruiz-Ortega
Journal:  Front Pharmacol       Date:  2018-10-17       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.